Boston Scientific’s Intracept Procedure, the first procedure designed to relieve vertebrogenic pain, has treated 50,000 patients.
In July 2024, there were more than 30,000 patients that had been treated with the Intracept system, according to information shared with Becker’s.
The minimally invasive procedure utilizes targeted radiofrequency energy to stop the basivertebral nerve from carrying pain signals to the brain.
The Intracept system uses the only FDA-approved device for the treatment of vertebrogenic low back pain, the release said.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
